We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veeva Expands Amgen Partnership With Global Vault CRM Rollout Plan
Read MoreHide Full Article
Key Takeaways
Amgen selected Veeva Vault CRM for global deployment, extending a partnership of more than a decade.
Veeva's Vault CRM has 180 live customers and expects to retain more than 70% CRM market share.
Commercial subscription revenue rose about 13% year over year on broad-based CRM, data and Crossix strength.
Veeva Systems (VEEV - Free Report) recently announced that Amgen (AMGN - Free Report) has selected its Vault CRM for a global deployment, extending a collaboration that has spanned more than a decade. The rollout is expected to support Amgen's commercial operations as it advances new therapies across worldwide markets.
The deal reinforces Veeva's strengthening commercial business, where management recently highlighted the best CRM quarter ever and continued enterprise adoption of Vault CRM during its latest earnings call. The Amgen win also adds momentum to Veeva's strategy of deepening relationships with large biopharma customers, an important driver of long-term subscription growth.
Likely Trend of VEEV Stock Following the News
Following the announcement, shares of VEEV traded flat in yesterday’s trading. Year to date, shares of the company have gained 16.8% compared with the industry’s 13.5% growth. However, the S&P 500 has risen 11.4% in the same timeframe.
Amgen's global adoption of Vault CRM strengthens Veeva's long-term commercial growth strategy by reinforcing its position as the preferred CRM partner for large biopharma companies. The win comes as management recently highlighted its strongest-ever CRM quarter, more than 180 live Vault CRM customers and growing confidence in retaining more than 70% market share in the CRM space.
Beyond expanding recurring subscription revenue, the deployment could create additional cross-sell opportunities across Veeva's broader commercial suite as global customers increasingly seek integrated, AI-enabled platforms for commercial operations.
VEEV currently has a market capitalization of $42.13 billion.
Image Source: Zacks Investment Research
More on the News
Amgen's decision to standardize on Veeva Vault CRM globally marks another major enterprise validation for the company's next-generation commercial platform, extending a partnership that has lasted for more than a decade. Amgen said that the migration will help accelerate the delivery of new therapies worldwide with greater speed and agility, while Veeva noted that the platform will serve as the commercial foundation for launching innovative medicines across global markets.
The latest deployment further demonstrates how leading pharmaceutical and biotechnology companies are increasingly turning to Vault CRM as they modernize commercial operations on a unified, life sciences-focused platform.
Vault CRM's expanding adoption is being driven by its AI-enabled commercial capabilities that help life sciences companies improve engagement with healthcare professionals. As part of the broader Vault CRM Suite, the platform supports an agentic commercial model that combines commercial workflows with AI-powered capabilities such as Agentic Call Report, which generates commercial evidence and helps uncover previously hidden treatment barriers.
These features enable field teams to streamline customer interactions while providing commercial organizations with deeper insights, making the platform increasingly attractive for large pharmaceutical and biotech companies seeking integrated commercial solutions instead of fragmented legacy systems.
The Amgen win also aligns with the strong commercial momentum highlighted during Veeva's latest earnings call. Management described fiscal second-quarter 2027 as its best CRM quarter ever, with commercial subscription revenue growing about 13% year over year on broad-based strength across CRM, content, data and Crossix.
Veeva also emphasized that Vault CRM now has more than 180 live customers, including large enterprise deployments, while management reiterated confidence in maintaining more than 70% market share in life sciences CRM as customers increasingly prioritize proven, AI-enabled commercial platforms.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global healthcare CRM market size was valued at $21.5 billion in 2025 and is projected to grow from $23.3 billion in 2026 to $35.7 billion by 2033, at a CAGR of 6.2% from 2026 to 2033.
The rising demand for structured data and automation in healthcare organizations is expected to drive market growth.
Other News
Recently, Veeva exited the second quarter of fiscal 2027 with better-than-expected results, wherein both earnings and revenues beat the Zacks Consensus Estimate. The company also raised its fiscal 2027 outlook. Strong execution across Commercial Solutions and R&D and Quality Solutions, along with continued momentum in newer growth areas, remained encouraging.
VEEV’s Zacks Rank & Key Picks
Currently, VEEV has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) and Veracyte (VCYT - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 41.8%.
View the Zacks #1 Rank List
Image: Bigstock
Veeva Expands Amgen Partnership With Global Vault CRM Rollout Plan
Key Takeaways
Veeva Systems (VEEV - Free Report) recently announced that Amgen (AMGN - Free Report) has selected its Vault CRM for a global deployment, extending a collaboration that has spanned more than a decade. The rollout is expected to support Amgen's commercial operations as it advances new therapies across worldwide markets.
The deal reinforces Veeva's strengthening commercial business, where management recently highlighted the best CRM quarter ever and continued enterprise adoption of Vault CRM during its latest earnings call. The Amgen win also adds momentum to Veeva's strategy of deepening relationships with large biopharma customers, an important driver of long-term subscription growth.
Likely Trend of VEEV Stock Following the News
Following the announcement, shares of VEEV traded flat in yesterday’s trading. Year to date, shares of the company have gained 16.8% compared with the industry’s 13.5% growth. However, the S&P 500 has risen 11.4% in the same timeframe.
Amgen's global adoption of Vault CRM strengthens Veeva's long-term commercial growth strategy by reinforcing its position as the preferred CRM partner for large biopharma companies. The win comes as management recently highlighted its strongest-ever CRM quarter, more than 180 live Vault CRM customers and growing confidence in retaining more than 70% market share in the CRM space.
Beyond expanding recurring subscription revenue, the deployment could create additional cross-sell opportunities across Veeva's broader commercial suite as global customers increasingly seek integrated, AI-enabled platforms for commercial operations.
VEEV currently has a market capitalization of $42.13 billion.
Image Source: Zacks Investment Research
More on the News
Amgen's decision to standardize on Veeva Vault CRM globally marks another major enterprise validation for the company's next-generation commercial platform, extending a partnership that has lasted for more than a decade. Amgen said that the migration will help accelerate the delivery of new therapies worldwide with greater speed and agility, while Veeva noted that the platform will serve as the commercial foundation for launching innovative medicines across global markets.
The latest deployment further demonstrates how leading pharmaceutical and biotechnology companies are increasingly turning to Vault CRM as they modernize commercial operations on a unified, life sciences-focused platform.
Vault CRM's expanding adoption is being driven by its AI-enabled commercial capabilities that help life sciences companies improve engagement with healthcare professionals. As part of the broader Vault CRM Suite, the platform supports an agentic commercial model that combines commercial workflows with AI-powered capabilities such as Agentic Call Report, which generates commercial evidence and helps uncover previously hidden treatment barriers.
These features enable field teams to streamline customer interactions while providing commercial organizations with deeper insights, making the platform increasingly attractive for large pharmaceutical and biotech companies seeking integrated commercial solutions instead of fragmented legacy systems.
The Amgen win also aligns with the strong commercial momentum highlighted during Veeva's latest earnings call. Management described fiscal second-quarter 2027 as its best CRM quarter ever, with commercial subscription revenue growing about 13% year over year on broad-based strength across CRM, content, data and Crossix.
Veeva also emphasized that Vault CRM now has more than 180 live customers, including large enterprise deployments, while management reiterated confidence in maintaining more than 70% market share in life sciences CRM as customers increasingly prioritize proven, AI-enabled commercial platforms.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global healthcare CRM market size was valued at $21.5 billion in 2025 and is projected to grow from $23.3 billion in 2026 to $35.7 billion by 2033, at a CAGR of 6.2% from 2026 to 2033.
The rising demand for structured data and automation in healthcare organizations is expected to drive market growth.
Other News
Recently, Veeva exited the second quarter of fiscal 2027 with better-than-expected results, wherein both earnings and revenues beat the Zacks Consensus Estimate. The company also raised its fiscal 2027 outlook. Strong execution across Commercial Solutions and R&D and Quality Solutions, along with continued momentum in newer growth areas, remained encouraging.
VEEV’s Zacks Rank & Key Picks
Currently, VEEV has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) and Veracyte (VCYT - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 41.8%.